Get the Stockscreener App
39.57
2.59%
1.00
Qiagen Nv stock is traded at $39.57, with a volume of 1.24M.
It is up +2.59% in the last 24 hours and down -19.01% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$38.57
Open:
$39.21
24h Volume:
1.24M
Relative Volume:
1.24
Market Cap:
$8.55B
Revenue:
$1.97B
Net Income/Loss:
$92.93M
P/E Ratio:
97.32
EPS:
0.4066
Net Cash Flow:
$459.60M
1W Performance:
-0.75%
1M Performance:
-19.01%
6M Performance:
-18.25%
1Y Performance:
-10.26%
1-Day Range:
$38.80
$39.59
1-Week Range:
$38.49
$40.21
52-Week Range:
$38.49
$49.30
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
39.57 | 8.55B | 1.97B | 92.93M | 459.60M | 0.4066 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen, Bio-Techne downgraded at Baird amid NIH funding concerns - MSN
QIAGEN NV : Berenberg remains its Buy rating -February 21, 2025 at 03:41 am EST - Marketscreener.com
Baird Downgrades Qiagen N.V. (BIT:1QGEN) - Nasdaq
Baird Downgrades Qiagen N.V. (QGEN) - MSN
In vitro diagnostics Market Poised for Significant Growth to Reach value of USD 133.24 Billion from 2025 to 2034 - GlobeNewswire Inc.
Baird Downgrades Qiagen N.V. (BRSE:QGEN) - Nasdaq
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Baird Downgrades Qiagen N.V. (LSE:0RLT) - Nasdaq
Qiagen downgraded to Neutral from Outperform at Baird - TipRanks
QIAGEN opens new data center in Melbourne - MSN
Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials Driving The Negative Sentiment? - Simply Wall St
Institutional owners may take dramatic actions as Qiagen N.V.'s (NYSE:QGEN) recent 5.6% drop adds to one-year losses - Yahoo Finance
QIAGEN NV : Deutsche Bank keeps its Buy rating -February 14, 2025 at 07:01 am EST - Marketscreener.com
William Blair Issues Negative Forecast for Qiagen Earnings - MarketBeat
Qiagen (NYSE:QGEN) Reaches New 12-Month Low Following Analyst Downgrade - MarketBeat
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region - br.ADVFN.com
QIAGEN opens new data center in Melbourne By Investing.com - Investing.com Nigeria
Major Bioinformatics Milestone: QIAGEN's 8th Global Data Hub Powers Asia-Pacific Healthcare Revolution - StockTitan
Companion Diagnostics Market Trends 2019-2024 and Forecast to 2034 - GlobeNewswire Inc.
QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation - br.ADVFN.com
Qiagen (NYSE:QGEN) Shares Gap DownShould You Sell? - MarketBeat
Qiagen (NYSE:QGEN) Given New $48.00 Price Target at UBS Group - MarketBeat
Qiagen at low since July, Merck weakUSA cuts research -February 10, 2025 at 05:28 am EST - Marketscreener.com
Qiagen (NYSE:QGEN) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Qiagen (NYSE:QGEN) Updates Q1 2025 Earnings Guidance - MarketBeat
Qiagen (NYSE:QGEN) Updates FY 2025 Earnings Guidance - MarketBeat
Qiagen Exceeds 2024 Financial Outlook with Solid Growth - TipRanks
Qiagen targets 4% CER sales growth for 2025 with key portfolio advancements - MSN
QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand - MSN
QIAGEN NV : DZ Bank maintains a Buy rating -February 07, 2025 at 09:42 am EST - Marketscreener.com
Qiagen N.V. (NYSE:QGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Sequencing Reagents Industry Eyes $15.84 Billion Valuation by 2030Thermo Fisher Scientific, Abzena, Illumina, QIAGEN, and Pacific Biosciences of California Lead the Competition - Yahoo Finance
Qiagen (NYSE:QGEN) Receives $50.07 Consensus Price Target from Brokerages - MarketBeat
UBS Adjusts QIAGEN Price Target to $48 From $50, Maintains Neutral Rating -February 07, 2025 at 11:23 am EST - Marketscreener.com
QIAGEN Reports Solid Growth and Exceeds 2024 Outlook - TipRanks
Qiagen N.V. Q4 2024 Earnings Call: Strong Growth Amid Challenges - TipRanks
Wellington Management Group LLP Increases Stake in Qiagen NV - GuruFocus.com
Qiagen: Decent end to 2024 -February 06, 2025 at 09:58 am EST - Marketscreener.com
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.06%
3.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):